Protagonist Therapeutics (PTGX) Tops Q3 EPS by 1c

Protagonist Therapeutics (NASDAQ: PTGX) reported Q3 EPS of ($0.62), $0.01 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $4.71 million versus the consensus estimate of $4.51 million.

For earnings history and earnings-related data on Protagonist Therapeutics (PTGX) click here.

You May Also Be Interested In

• Microsoft plans data center push to triple its computing power - Bloomberg
• IBEX Limited (IBEX) Tops Q4 EPS by 6c; offers guidance
• Laser Photonics prices $7.9M public offering at $0.75 per share